Caitlyn E Painter1, Anne M Suskind2. 1. Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Kaiser Permanente East Bay-University of California, San Francisco. 2. Departments of Urology and Gynecology, Obstetrics and Reproductive Sciences, University of San Francisco, San Francisco, California.
Abstract
PURPOSE OF REVIEW: To present the current literature on the pharmacologic management of overactive bladder, including combination therapies, agents still in clinical development, and special considerations related to individuals with cognitive decline, frailty and cardiovascular risk. RECENT FINDINGS: Combination therapy is shown to be more effective than monotherapy, without additional side effects. Preliminary studies on novel treatment methods, including new medications, as well was novel use of established medications, demonstrates improved efficacy with a favorable side effect profile. Investigation into new target pathways may be an area for future pharmacologic development. Special consideration should be given when prescribing anti-muscarinic medication in the frail adult population. Overactive bladder has been associated with frailty and anti-muscarinic medications have been associated with the worsening cognitive decline. SUMMARY: Combination therapy is a safe and effective alternative to patients with refractory overactive bladder. Caution should be taken in prescribing medications for the frail older adult, and alternative first- and third-line treatments should be considered. Future studies should involve long term data on safety and outcomes stratified by age with objective measurements of cognition and frailty.
PURPOSE OF REVIEW: To present the current literature on the pharmacologic management of overactive bladder, including combination therapies, agents still in clinical development, and special considerations related to individuals with cognitive decline, frailty and cardiovascular risk. RECENT FINDINGS: Combination therapy is shown to be more effective than monotherapy, without additional side effects. Preliminary studies on novel treatment methods, including new medications, as well was novel use of established medications, demonstrates improved efficacy with a favorable side effect profile. Investigation into new target pathways may be an area for future pharmacologic development. Special consideration should be given when prescribing anti-muscarinic medication in the frail adult population. Overactive bladder has been associated with frailty and anti-muscarinic medications have been associated with the worsening cognitive decline. SUMMARY: Combination therapy is a safe and effective alternative to patients with refractory overactive bladder. Caution should be taken in prescribing medications for the frail older adult, and alternative first- and third-line treatments should be considered. Future studies should involve long term data on safety and outcomes stratified by age with objective measurements of cognition and frailty.
Authors: M Song; J H Kim; K-S Lee; J Z Lee; S-J Oh; J T Seo; J B Choi; S W Kim; S J Rhee; M-S Choo Journal: Int J Clin Pract Date: 2014-11-01 Impact factor: 2.503
Authors: Anne M Suskind; Kathryn Quanstrom; Shoujun Zhao; Mark Bridge; Louise C Walter; John Neuhaus; Emily Finlayson Journal: Urology Date: 2017-05-11 Impact factor: 2.649
Authors: Joel R Gever; Rothschild Soto; Robert A Henningsen; Renee S Martin; David H Hackos; Sandip Panicker; Werner Rubas; Ian B Oglesby; Michael P Dillon; Marcos E Milla; Geoffrey Burnstock; Anthony P D W Ford Journal: Br J Pharmacol Date: 2010-07 Impact factor: 8.739
Authors: David D Rahn; Cassandra Carberry; Tatiana V Sanses; Mamta M Mamik; Renée M Ward; Kate V Meriwether; Cedric K Olivera; Husam Abed; Ethan M Balk; Miles Murphy Journal: Obstet Gynecol Date: 2014-12 Impact factor: 7.661
Authors: David Rich Ellington; Jeffery Michael Szychowski; Joseph Michael Malek; Kimberly Anne Gerten; Kathryn Larsen Burgio; Holly Elizabeth Richter Journal: Female Pelvic Med Reconstr Surg Date: 2016 Jul-Aug Impact factor: 2.091